Risk factors
CareDx (CDNA) risk factors
Item 1A of every CareDx, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors73 risks11 new4 dropped19 reworded
CMS repriced the AlloSure Kidney test to $2,753, resulting in an $88 price decrease.
Filed Feb 25, 2026 - FY2024 10-K risk factors66 risks
CareDx depends heavily on Medicare reimbursement and sales of its AlloSure and AlloMap transplant testing solutions. Operations face intense competition from traditional biopsies and evolving diagnostic technologies. Regulatory oversight by the FDA and CLIA creates significant compliance burdens and potential operational hurdles.
Filed Feb 28, 2025